Pyruvate kinase activators for use in treating blood disorders
申请人:Agios Pharmaceuticals, Inc.
公开号:US11040036B2
公开(公告)日:2021-06-22
Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
申请人:Agios Pharmaceuticals, Inc.
公开号:EP3668513B1
公开(公告)日:2021-11-10
CARBACEPHEM BETA-LACTAM ANTIBIOTICS
申请人:Wagman Allan Scott
公开号:US20110224186A1
公开(公告)日:2011-09-15
Carbacephem β-lactam antibiotics having the following chemical structure (I) are disclosed:
including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar
2
, X, R
1
and R
2
are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant
Staphylococcus
spp.
[EN] CARBACEPHEM BETA-LACTAM ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES DE TYPE BÉTA-LACTAME À BASE DE CARBACÉPHÈME
申请人:ACHAOGEN INC
公开号:WO2010030810A1
公开(公告)日:2010-03-18
Carbacephem β-lactam antibiotics having structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, X, R1 and R2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.